New NICE guidelines for PCOS renamed PMOS
NICE has published new guidelines for polycystic ovary syndrome, now renamed PMOS, aiming to improve diagnosis and treatment.
The Full Story
A plain summary built from the channels that reported this story.
New guidelines from the National Institute for Health and Care Excellence (NICE) have renamed polycystic ovary syndrome (PCOS) to polycystic ovary syndrome metabolic syndrome (PMOS), aiming to improve diagnosis and treatment for the condition that affects around one in eight women.
The updated guidance marks a shift in understanding the condition as a whole-body endocrine and metabolic disorder, rather than just a fertility issue. The name change reflects this broader view, with experts emphasising that PMOS has lifelong implications, including increased risks of type 2 diabetes, cardiovascular disease, and mental health problems such as anxiety and depression.
Patient advocates have welcomed the move, noting that diagnosis has historically been slow and inconsistent. Caroline Andrews, who lives with the condition, said she was diagnosed in 2002 after about 15 visits to the GP over eight years. She was initially told to "go away" until she wanted to have children. Data from the All-Party Parliamentary Group on PCOS, supported by the charity Verity, found that a third of those diagnosed waited over four years, and an estimated 70% of people with the condition remain undiagnosed.
Chand Kaur, from the charity PCOS Relief, said the new guidance will help safeguard fertility treatment and provide better mental health support from an early stage. "Supporting that at the early stages is life changing because it's your mental health," she said.
The guidelines recommend that women who suspect they have the condition should speak to their GP and request both a blood test and an ultrasound for diagnosis. The advice is intended to reduce stigma and encourage earlier intervention.
Both charities stressed that medication alone is not a solution; lifestyle changes remain a key part of managing the condition. The new NICE guidelines are expected to standardise care across the NHS and improve outcomes for millions of women.
On screen
Stills are sampled automatically at 60-second intervals. Where shown, the still is the nearest available frame from the relevant broadcast segment and is included to show what was on screen during that part of the broadcast. A still may not correspond to the exact second of a quoted phrase.
Key Claims
Claims reported during this story's coverage, mapped by channel. Ordered by how many channels carried each claim.
| Claim | Channel 5 |
|---|---|
| A third of those diagnosed waited over four years, and about 70% of people with the condition are undiagnosed. | |
| Diagnosis can be made through a blood test or an ultrasound. | |
| The condition affects approximately one in eight women. |
Channel Perspectives
What each channel focused on, with key quotes.
The channel focused on personal stories and patient advocacy, using interviews with a patient and a charity representative to highlight the emotional and practical impact of the condition. The tone was empathetic and informative, with a strong call to action for women to seek diagnosis. The segment also emphasised the name change and the broader metabolic nature of the condition.
- “So as an individual, it's been something that's happened throughout my life, of course. So I was diagnosed in 2002 after probably about 15 visits to the GP over a period of eight years.”
- “I think now with the new name change, it's going to be more than just an ovarian condition. It's actually a whole endocrine body condition.”
- “Supporting that at the early stages is life changing because it's your mental health, isn't it? Especially if you're not being listened to.”
Broadcast Timeline
News broadcasts tracked for this story, in time order.